Serum and salivary macrophage migration inhibitory factor in patients with oral squamous cell carcinoma

de Souza,Mariana   Barbosa; Curioni,Otávio   Alberto; Kanda,Jossi  Ledo; De Carvalho,Marcos  Brasilino

doi:10.3892/ol.2014.2513

Serum and salivary macrophage migration inhibitory factor in patients with oral squamous cell carcinoma

Authors:
- Mariana Barbosa de Souza
- Otávio Alberto Curioni
- Jossi Ledo Kanda
- Marcos Brasilino De Carvalho
View Affiliations

Affiliations: Department of Radiology and Oncology, Medical School, University of São Paulo, São Paulo 01246903, Brazil, Laboratory of Molecular Biology, Heliópolis Hospital, São Paulo 04231030, Brazil, Department of Head and Neck Surgery, Padre Anchieta Teaching Hospital, ABC Medical School, São Bernardo do Campo 09715090, Brazil
Published online on: September 9, 2014 https://doi.org/10.3892/ol.2014.2513
Pages: 2267-2275

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The overexpression of macrophage migration inhibitory factor (MIF) has been identified in a variety of tumors and the investigation of its molecular mechanisms in tumor progression is a key topic of research. The present study aimed to investigate MIF as a potential marker for disease control or recurrence, and to assess the association between serum and salivary MIF and the clinicopathological characteristics of patients with oral squamous cell carcinoma (OSCC). Serum and salivary samples were collected prior to and following the surgical treatment of 50 patients with OSCC. MIF concentrations were assessed by enzyme‑linked immunosorbent assay and the adopted level of statistical significance was P<0.05. The results revealed that serum MIF concentrations were significantly reduced following tumor resection in OSCC patients. Furthermore, higher preoperative salivary MIF concentrations were observed in patients with larger tumors and in those who succumbed to the disease. In conclusion, high salivary and serological MIF concentrations were identified in patients with OSCC. Nevertheless, only serological MIF concentrations may be considered as a potential marker for the early detection of OSCC recurrence once the salivary levels, prior and following treatment, do not show any significant differences.

View Figures

View References

1	Warnakulasuriya S: Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 45:309–316. 2009.
2	de Camargo Cancela M, Voti L, Guerra-Yi M, Chapuis F, Mazuir M and Curado MP: Oral cavity cancer in developed and in developing countries: population-based incidence. Head Neck. 32:357–367. 2010.
3	INCA National Cancer Institute. Estimate/2012-Cancer Incidence in Brazil. Ministry of Health; Brasília, Brazil: pp. 982009
4	Gillison ML: Current topics in the epidemiology of oral cavity and oropharyngeal cancers. Head Neck. 29:779–792. 2007.
5	Marques LA, Eluf-Neto J, Figueiredo RA, Góis-Filho JF, Kowalski LP, Carvalho MB, Abrahão M and Wünsch-Filho V: Oral health, hygiene practices and oral cancer. Rev Saude Publica. 42:471–479. 2008.
6	Palka KT, Slebos RJ and Chung CH: Update on molecular diagnostic tests in head and neck cancer. Semin Oncol. 35:198–210. 2008.
7	Hu S, Arellano M, Boontheung P, Wang J, Zhou H, Jiang J, Elashoff D, et al: Salivary proteomics for oral cancer biomarker discovery. Clin Cancer Res. 14:6246–6252. 2008.
8	Nagler RM: Saliva as a tool for oral cancer diagnosis and prognosis. Oral Oncol. 45:1006–1010. 2009.
9	Douglas WG, Tracy E, Tan D, Yu J, Hicks WL Jr, Rigual NR, Loree TR, et al: Development of head and neck squamous cell carcinoma is associated with altered cytokine responsiveness. Mol Cancer Res. 2:585–593. 2004.
10	Feller L, Altini M and Lemmer J: Inflammation in the context of oral cancer. Oral Oncol. 49:887–892. 2013.
11	Candido J and Hagemann T: Cancer-related inflammation. J Clin Immunol. 33(Suppl 1): S79–S84. 2013.
12	Mantovani A, Garlanda C and Allavena P: Molecular pathways and targets in cancer-related inflammation. Ann Med. 42:161–170. 2010.
13	Bloom BR and Bennett B: Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science. 153:80–82. 1966.
14	David JR: Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA. 56:72–77. 1966.
15	Calandra T and Roger T: Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol. 3:791–800. 2003.
16	Bucala R and Donnelly SC: Macrophage migration inhibitory factor: a probable link between inflammation and cancer. Immunity. 26:281–285. 2007.
17	Mitchell RA and Bucala R: Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). Semin Cancer Biol. 10:359–366. 2000.
18	Mitchell RA: Mechanisms and effectors of MIF-dependent promotion of tumourigenesis. Cell Signal. 16:13–19. 2004.
19	Grieb G, Merk M, Bernhagen J and Bucala R: Macrophage migration inhibitory factor (MIF): a promising biomarker. Drug News Perspect. 23:257–264. 2010.
20	Yasasever V, Camlica H, Duranyildiz D, Oguz H, Tas F and Dalay N: Macrophage migration inhibitory factor in cancer. Cancer Invest. 25:715–719. 2007.
21	Muramaki M, Miyake H, Yamada Y and Hara I: Clinical utility of serum macrophage migration inhibitory factor in men with prostate cancer as a novel biomarker of detection and disease progression. Oncol Rep. 15:253–257. 2006.
22	Lee H, Rhee H, Kang HJ, et al: Macrophage migration inhibitory factor may be used as an early diagnostic marker in colorectal carcinomas. Am J Clin Pathol. 129:772–779. 2008.
23	He XX, Yang J, Ding YW, Liu W, Shen QY and Xia HH: Increased epithelial and serum expression of macrophage migration inhibitory factor (MIF) in gastric cancer: potential role of MIF in gastric carcinogenesis. Gut. 55:797–802. 2006.
24	Meyer-Siegler KL, Bellino MA and Tannenbaum M: Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma. Cancer. 94:1449–1456. 2002.
25	Hira E, Ono T, Dhar DK, El-Assal ON, Hishikawa Y, Yamanoi A and Nagasue N: Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma. Cancer. 103:588–598. 2005.
26	Xia HH, Yang Y, Chu KM, Gu Q, Zhang YY, He H, Wong WM, et al: Serum macrophage migration-inhibitory factor as a diagnostic and prognostic biomarker for gastric cancer. Cancer. 115:5441–5449. 2009.
27	Kindt N, Lechien J, Decaestecker C, Rodriguez A, Chantrain G, Remmelink M, Laurent G, et al: Expression of macrophage migration-inhibitory factor is correlated with progression in oral cavity carcinomas. Anticancer Res. 32:4499–4505. 2012.
28	Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ and Beach DH: A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med. 190:1375–1382. 1999.
29	Denz A, Pilarsky C, Muth D, Rückert F, Saeger HD and Grützmann R: Inhibition of MIF leads to cell cycle arrest and apoptosis in pancreatic cancer cells. J Surg Res. 160:29–34. 2010.
30	Li GQ, Xie J, Lei XY and Zhang L: Macrophage migration inhibitory factor regulates proliferation of gastric cancer cells via the PI3K/Akt pathway. World J Gastroenterol. 15:5541–5548. 2009.
31	Schrader J, Deuster O, Rinn B, Schulz M, Kautz A, Dodel R, Meyer B, et al: Restoration of contact inhibition in human glioblastoma cell lines after MIF knockdown. BMC Cancer. 9:4642009.
32	Rendon BE, Willer SS, Zundel W and Mitchell RA: Mechanisms of macrophage migration inhibitory factor (MIF)-dependent tumor microenvironmental adaptation. Exp Mol Pathol. 86:180–185. 2009.
33	Calandra T, Bernhagen JL, Mitchell RA and Bucala R: The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med. 179:1895–1902. 1994.
34	Camlica H, Duranyildiz D, Oguz H, Oral EN and Yasasever V: The diagnostic value of macrophage migration inhibitory factor (MIF) in gastric cancer. Pathol Oncol Res. 14:79–83. 2008.
35	Fang W, Li X, Jiang Q, Liu Z, Yang H, Wang S, Xie S, et al: Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China. J Transl Med. 6:322008.
36	Kamimura A, Kamachi M, Nishihira J, Ogura S, Isobe H, Dosaka-Akita H, Ogata A, et al: Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung. Cancer. 89:334–341. 2000.
37	Mohri Y, Mohri T, Wei W, Qi YJ, Martin A, Miki C, Kusunoki M, et al: Identification of macrophage migration inhibitory factor and human neutrophil peptides 1–3 as potential biomarkers for gastric cancer. Br J Cancer. 101:295–302. 2009.
38	Ren Y, Law S, Huang X, Lee PY, Bacher M, Srivastava G and Wong J: Macrophage migration inhibitory factor stimulates angiogenic factor expression and correlates with differentiation and lymph node status in patients with esophageal squamous cell carcinoma. Ann Surg. 242:55–63. 2005.
39	Tomiyasu M, Yoshino I, Suemitsu R, Okamoto T and Sugimachi K: Quantification of macrophage migration inhibitory factor mRNA expression in non-small cell lung cancer tissues and its clinical significance. Clin Cancer Res. 8:3755–3760. 2002.
40	Xia HH, Zhang ST, Lam SK, Lin MC, Kung HF and Wong BC: Expression of macrophage migration inhibitory factor in esophageal squamous cell carcinoma and effects of bile acids and NSAIDs. Carcinogenesis. 26:11–15. 2005.
41	Cooke G, Armstrong ME and Donnelly SC: Macrophage migration inhibitory factor (MIF), enzymatic activity and the inflammatory response. Biofactors. 35:165–168. 2009.
42	Sanchez-Zamora Y, Terrazas LI, Vilches-Flores A, et al: Macrophage migration inhibitory factor is a therapeutic target in treatment of non-insulin-dependent diabetes mellitus. FASEB J. 24:2583–2590. 2010.
43	Bucala R: MIF Rediscovered. MIF, A Most Interesting Factor. World Scientific Press; London: 2007
44	Baugh JA, Chitni S, Donnelly SC, et al: A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun. 3:170–176. 2002.
45	Donn RP, Shelley E, Ollier WE, et al: A novel 5′-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 44:1782–1785. 2001.
46	Sun B, Nishihira J, Yoshiki T, et al: Macrophage migration inhibitory factor promotes tumor Invasion and metastasis via the Rho-dependent pathway. Clin Cancer Res. 11:1050–1058. 2005.
47	Funamizu N, Hu C, Lacy C, Schetter A, Zhang G, He P, et al: Macrophage migration inhibitory factor (MIF) induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma. Int J Cancer. Jul 23–2013.(Epub ahead of print).
48	Han I, Lee MR, Nam KW, Oh JH, Moon KC and Kim HS: Expression of macrophage migration inhibitory factor relates to survival in high-grade osteosarcoma. Clin Orthop Relat Res. 466:2107–2113. 2008.
49	Liu H, Chen G, Zhang W, et al: Overexpression of macrophage migration inhibitory factor in adenoid cystic carcinoma: correlation with enhanced metastatic potential. J Cancer Res Clin Oncol. 139:287–295. 2013.
50	Suzuki F, Nakamaru Y, Oridate N, Homma A, Nagahashi T, Yamaguchi S, Nishihira J, et al: Prognostic significance of cytoplasmic macrophage migration inhibitory factor expression in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy. Oncol Rep. 13:59–64. 2005.
51	Verjans E, Noetzel E, Bektas N, Schütz AK, Lue H, Lennartz B, Hartmann A, et al: Dual role of macrophage migration inhibitory factor (MIF) in human breast cancer. BMC Cancer. 9:2302009.
52	Lim S, Choong LY, Kuan CP, Yunhao C and Lim YP: Regulation of macrophage inhibitory factor (MIF) by epidermal growth factor receptor (EGFR) in the MCF10AT model of breast cancer progression. J Proteome Res. 8:4062–4076. 2009.